|Dr. Alon Seri-Levy||Co-Founder, CEO & Director||425||N/A||1961|
|Mr. Gilad Mamlok||Chief Financial Officer||345||N/A||1968|
|Mr. Itzik Yosef||VP of Operations||158||N/A||1976|
|Prof. David Avnir||Co-Founder||N/A||N/A||N/A|
|Dr. Karine Neimann||VP of Projects & Planning and Chief Chemist||N/A||N/A||1971|
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN, which has completed Phase II clinical trials for the treatment of acne vulgaris; and Epsolay that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.
Sol-Gel Technologies Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.